ArticleIranian journal of pathology2019
Role of FGFR3 in Urothelial Carcinoma.
Article in Iranian journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Immunohistochemical evaluation of molecular subtypes in muscle invasive bladder cancer with demographic correlation.BMC cancer · 2026Article
- Myxoid glioneuronal tumor of the septum pellucidum with concurrent dualFrontiers in oncology · 2026Article
- Diagnostic and Prognostic Implications of FGFR3, TP53 Mutation and Urinary Biomarkers in Urothelial Carcinoma in Pakistani Cohort.Journal of clinical medicine · 2025Article
- The Role of FGFR3 in the Progression of Bladder Cancer.Cancers · 2025Article
- Review of recent molecular pathology of bladder urothelial carcinoma.Discover oncology · 2025Review
- FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Journal of Korean medical science · 2024Review
- Article
- Article
- The Ketone Bridge Between the Heart and the Bladder: How Fast Should We Go?International neurourology journal · 2024Article
- Analysis of urine cell-free DNA in bladder cancer diagnosis by emerging bioactive technologies and materials.Frontiers in bioengineering and biotechnology · 2024Review
- P53, CK20, and FGFR3 Overexpression is Associated with the Characteristics of Urothelial Cell Carcinoma of the BladderAsian Pacific journal of cancer prevention : APJCP · 2023Article
- Landscape of the intratumroal microenvironment in bladder cancer:Computational and structural biotechnology journal · 2023Article
- Review
- Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.International journal of molecular sciences · 2021Review
- Rare transitional cell carcinoma of the lacrimal sac.American journal of ophthalmology case reports · 2020Article
- Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.International journal of molecular sciences · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveThis study was undertaken to analyze the immunohistochemical expression of fibroblast growth factor receptor (FGFR3) in urothelial carcinoma and correlate its expression with the pathological stage, recurrence and other clinicopathological parameters. MATERIAL AND
methodsA retrospective study was undertaken on paraffin blocks of 55consecutiveurothelial carcinoma specimens in 28 months received in Sri Ramachandra Medical College, Chennai, India. Blocks with the sections containing the tumor and adjacent normal epithelium were chosen for the immunohistochemical (IHC) study of FGFR3.
resultsIHC expression of FGFR3 in high grade (HG) invasive urothelial carcinoma was positive in 18% cases, 66.7% of HG non-invasive urothelial and 82.6% of low grade (LG) non-invasive urothelial carcinomas. The FGFR3 expression was presented in 78.1% of non-invasive carcinoma. In case of invasive urothelial carcinoma, the FGFR3 positivity was observed in 18.2% of tumors (
conclusionThe expression of FGFR3 is higher in low grade, non-invasive tumors and recurrent non-invasive tumors. The targeted therapy for FGFR3 may be used as one of the modes of treatment for urothelial carcinoma. It can also be used as a marker to determine the grade in difficult cases and the risk of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.